These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 12733143)

  • 1. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in multiple myeloma.
    Kyle RA
    Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
    Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
    Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
    Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP; Liautard J; Klein B; Brochier J
    Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
    Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
    Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine network in human multiple myeloma.
    Klein B; Bataille R
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):273-84. PubMed ID: 1582974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data.
    Lauta VM
    Cytokine; 2001 Nov; 16(3):79-86. PubMed ID: 11741345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
    Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
    Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
    Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.